PATENT COOPERATION TREATY

PCT

INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY (Chapter I of the Patent Cooperation Treaty)

(PCT Rule 44bis)

Applicant's or agent's file reference 002441.00093	FOR FURTHER ACTION	See item 4 below	
International application No. PCT/US2004/030032	International filing date (day/month/year) 15 September 2004 (15.09.2004)	Priority date (day/month/year) 15 September 2003 (15.09.2003)	
International Patent Classification (8th edition unless older edition indicated) See relevant information in Form PCT/ISA/237			
Applicant CHIRON CORPORATION			

1.	 This international preliminary report on patentability (Chapter I) is issued by the International Bureau on behalf of the International Searching Authority under Rule 44 bis. 1(a). 			
2.	This REPORT consists of a total	of 5 sheets, including this cover sheet.		
		nce to the written opinion of the International Searching Authority should be read as a reference eport on patentability (Chapter I) instead.		
3.	This report contains indications r	relating to the following items:		
	Box No. I	Basis of the report		
	Box No. II	Priority		
	Box No. III	Non-establishment of opinion with regard to novelty, inventive step and industrial applicability		
	Box No. IV	Lack of unity of invention		
	Box No. V	Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement		
	Box No. VI	Certain documents cited		
	Box No. VII	Certain defects in the international application		
	Box No. VIII	Certain observations on the international application		
4.	4. The International Bureau will communicate this report to designated Offices in accordance with Rules 44 <i>bis</i> .3(c) and 93 <i>bis</i> .1 but not, except where the applicant makes an express request under Article 23(2), before the expiration of 30 months from the priority date (Rule 44 <i>bis</i> .2).			

Date of issuance of this report 16 March 2006 (16.03.2006) Authorized officer The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland Yolaine Cussac Facsimile No. +41 22 740 14 35 Telephone No. +41 22 338 70 80

Form PCT/IB/373 (January 2004)

PATENT COOPERATION TREATY

From the INTERNAT	IONAL SEARCE	ING AUTH	ORITY			
To: REBECCA M. HALE CHIRON CORPORATION 4560 HORTON STREET EMERYVILLE, CA 94608-2916			PCTREC'D 0 8 DEC 2005 ITTEN OPIN ON OF THE ONAL SEAR WIPO AUTHORITY PC			
					(PCT Rule 43bis.1)	
					(day/month/year)	0 6 DEC 2005 .
Applicant'	s or agent's file re	eference			FOR FURTHER	ACTION See paragraph 2 below
002441.00	093 al application No		Internati	ional filing date	(day/month/year)	Priority date (day/month/year)
		•		ember 2004 (15.		15 September 2003 (15.09.2003)
PCT/US04 Internation	al Patent Classifi	cation (IPC)	or both na	tional classificat	tion and IPC	
IPC(7): A6	51K 39/385, 39/11	16, 39/00, 39/	02, 39/38,	, 39/09 and US	Cl.: 424/197.11, 203.1	, 192.1, 190.1, 184.1, 244.1
Applicant						
CHIRON	CORPORATION					
1. This o	pinion contains in	ndications rel	ating to th	e following iten	ns:	`₩.
	Box No. I	Basis of the	opinion			
	Box No. II Priority					
	Box No. III	Non-establi	ishment of	f opinion with re	gard to novelty, inver	ntive step and industrial applicability
\boxtimes	Box No. IV	Lack of uni	ty of inve	ntion		
	Box No. V	V Reasoned statement under Rule 43bis.1(a)(i) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement				
	Box No. VI	Certain doc	uments ci	ted		
	Box No. VII	Certain def	ects in the	international ap	plication	
	Box No. VIII Certain observations on the international application					
ים ודם ב	THER ACTIO	ini				
If a demand for international preliminary examination is made, this opinion will be considered to be a written opinion of the International Preliminary Examining Authority ("IPEA") except that this does not apply where the applicant chooses an Authority other than this one to be the IPEA and the chosen IPEA has notified the International Bureau under Rule 66.1bis(b) that written opinions of this International Searching Authority will not be so considered.						
If this opinion is, as provided above, considered to be a written opinion of the IPEA, the applicant is invited to submit to the IPEA a written reply together, where appropriate, with amendments, before the expiration of 3 months from the date of mailing of Form PCT/ISA/220 or before the expiration of 22 months from the priority date, whichever expires later. For further options, see Form PCT/ISA/220.						
got tutting operating the retained of the retained of the retained operating the retained o						
3. For further details, see notes to Form PCT/ISA/220.						
Name and mailing address of the ISA/ US Date of comp			Date of compl	etion of this opinion	Authorized officer	
Mail Stop PCT, Attn: ISA/US Commissioner for Patents 09 November			09 November	2005 (09.11.2005)	S. Devi, Ph.D. Janes Ford	
P.O. Box 1450 Alexandria, Virginia 22313-1450 Facsimile No. (571) 273-3201					Telephone No. (571) 272-1600	
+ Facsimile	170. (2/1) 6/3-36	.01		l		<u> </u>

Form PCT/ISA/237 (cover sheet) (April 2005)

WRITTEN OPINION OF THE INTERNATIONAL SEARCHING AUTHORITY

International application No.	
PCT/US04/30032	

 With regard to the language, this opinion has been established on the basis of: the international application in the language in which it was filed a translation of the international application into, which is the language of a translation furnished for the 	e purposes of
the international application in the language in which it was filed	e purposes of
	e purposes of
which is the language of a translation furnished for the	e purposes of
international search (Rules 12.3(a) and 23.1(b)).	-
With regard to any nucleotide and/or amino acid sequence disclosed in the international application and necessary invention, this opinion has been established on the basis of:	to the claimed
a. type of material	
a sequence listing	
table(s) related to the sequence listing	
b. format of material	
on paper	
in electronic form	
M decirone form	
c. time of filing/furnishing	
contained in the international application as filed.	,
filed together with the international application in electronic form.	
furnished subsequently to this Authority for the purposes of search.	
In addition, in the case that more than one version or copy of a sequence listing and/or table(s) relating thereto or furnished, the required statements that the information in the subsequent or additional copies is identical application as filed or does not go beyond the application as filed, as appropriate, were furnished.	o has been filed Il to that in the
4. Additional comments:	

Form PCT/ISA/237(Box No. I) (April 2005)

WRITTEN OPINION OF THE INTERNATIONAL SEARCHING AUTHORITY

International application No.	
PCT/US04/30032	

Box No. IV Lack of unity of invention				
1. In response to the invitation (Form PCT/ISA/206) to pay additional fees the applicant has, within the applicable time limit: paid additional fees paid additional fees under protest and, where applicable, the protest fee paid additional fees under protest but the applicable protest fee was not paid not paid additional fees This Authority found that the requirement of unity of invention is not complied with and chose not to invite the applicant to pay additional fees. This Authority considers that the requirement of unity of invention in accordance with Rule 13.1, 13.2 and 13.3 is complied with not complied with for the following reasons: See the lack of unity section of the International Search Report(Form PCT/ISA/210)				
4. Consequently, this opinion has been established in respect of the following parts of the international application: all parts. the parts relating to claims Nos. 1-17				

WRITTEN OPINION OF THE INTERNATIONAL SEARCHING AUTHORITY

Form PCT/ISA/237 (Box No. V) (April 2005)

International application No. PCT/US04/30032

1. Statement Novelty (N) Claims NONE Claims L17 NO Inventive step (IS) Claims L17 NO Industrial applicability (IA) Claims L17 NO Louing L17 NO 2. Citations and explanations: Claims 1-17 look novely under PCT Article 33(2) as being anticipated by CHIRON CORPORATION (WO 2004/041157 A2). CHIRON CORPORATION taught a composition comprising a combination of GBS 30 antigen having the amino acid sequence of SEQ ID NO: 2 or a fragment thereof, and GBS 322 antigen or a GBS saccharide antigen. The antigen combination in the composition can consist of 2-5 GBS entigens and includes GBS 80, GBS 104, GBS 276, GBS 91, GBS 184 etc.	Box No. V Reasoned statement under Rule 43 bis.1(a)(i) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement				
Inventive step (IS) Claims 1-17 NO Claims NONE Claims 1-17 NO Industrial applicability (IA) Claims 1-17 VES Claims NONE NO 2. Citations and explanations: Claims 1-17 lack novelty under PCT Article 33(2) as being anticipated by CHIRON CORPORATION (WO 2004/041157 A2). CHIRON CORPORATION taught a composition comprising a combination of GBS 80 antigen having the amino acid sequence of SEQ ID NO: 2 or a fragment thereof, and GBS 322 antigen or a GBS saccharide antigen. The antigen combination in the	1. Statement				
Inventive step (IS) Claims 1-17 NO Industrial applicability (IA) Claims 1-17 NO Industrial applicability (IA) Claims 1-17 VES Claims NONE NO 2. Citations and explanations: Claims 1-17 lack novelty under PCT Article 33(2) as being anticipated by CHIRON CORPORATION (WO 2004/041157 A2). CHIRON CORPORATION taught a composition comprising a combination of GBS 80 antigen having the amino acid sequence of SEQ ID NO: 2 or a fragment thereof, and GBS 322 antigen or a GBS saccharide antigen. The antigen combination in the	Novelty (N)	Claims	NONE	YES	
Industrial applicability (IA) Claims 1-17 VES Claims NONE 2. Citations and explanations: Claims 1-17 lack novelty under PCT Article 33(2) as being anticipated by CHIRON CORPORATION (WO 2004/041157 A2). CHIRON CORPORATION taught a composition comprising a combination of GBS 80 antigen having the amino acid sequence of SEQ ID NO: 2 or a fragment thereof, and GBS 322 antigen or a GBS saccharide antigen. The antigen combination in the	• • •				
Industrial applicability (IA) Claims 1-17 VES Claims NONE 2. Citations and explanations: Claims 1-17 lack novelty under PCT Article 33(2) as being anticipated by CHIRON CORPORATION (WO 2004/041157 A2). CHIRON CORPORATION taught a composition comprising a combination of GBS 80 antigen having the amino acid sequence of SEQ ID NO: 2 or a fragment thereof, and GBS 322 antigen or a GBS saccharide antigen. The antigen combination in the	Inscentive stan (IC)	Claima	NONE	VEQ	
Industrial applicability (IA) Claims 1-17 VES Claims NONE 2. Citations and explanations: Claims 1-17 lack novelty under PCT Article 33(2) as being anticipated by CHIRON CORPORATION (WO 2004/041157 A2). CHIRON CORPORATION taught a composition comprising a combination of GBS 80 antigen having the amino acid sequence of SEQ ID NO: 2 or a fragment thereof, and GBS 322 antigen or a GBS saccharide antigen. The antigen combination in the	inventive step (13)				
Claims NONE NO 2. Citations and explanations: Claims 1-17 lack novelty under PCT Article 33(2) as being anticipated by CHIRON CORPORATION (WO 2004/041157 A2). CHIRON CORPORATION taught a composition comprising a combination of GBS 80 antigen having the amino acid sequence of SEQ ID NO: 2 or a fragment thereof, and GBS 322 antigen or a GBS saccharide antigen. The antigen combination in the					
 Citations and explanations: Claims 1-17 lack novelty under PCT Article 33(2) as being anticipated by CHIRON CORPORATION (WO 2004/041157 A2). CHIRON CORPORATION taught a composition comprising a combination of GBS 80 antigen having the amino acid sequence of SEQ ID NO: 2 or a fragment thereof, and GBS 322 antigen or a GBS saccharide antigen. The antigen combination in the 	Industrial applicability (IA)				
2. Citations and explanations: Claims 1-17 lack novelty under PCT Article 33(2) as being anticipated by CHIRON CORPORATION (WO 2004/041157 A2). CHIRON CORPORATION taught a composition comprising a combination of GBS 80 antigen having the amino acid sequence of SEQ ID NO: 2 or a fragment thereof, and GBS 322 antigen or a GBS saccharide antigen. The antigen combination in the		Claims	NONE	NO	
Claims 1-17 lack novelty under PCT Article 33(2) as being anticipated by CHIRON CORPORATION (WO 2004/041157 A2). CHIRON CORPORATION taught a composition comprising a combination of GBS 80 antigen having the amino acid sequence of SEQ ID NO: 2 or a fragment thereof, and GBS 322 antigen or a GBS saccharide antigen. The antigen combination in the	2 Citations and explanations:			1.0000000000000000000000000000000000000	
	sequence of SEQ ID NO: 2 or a fragment thereof, at composition can consist of 2-5 GBS antigens and in	nd GBS 322 anticludes GBS 80,	igen or a GBS saccharide antigen. The an GBS 104, GBS 276, GBS 91, GBS 184 e	tigen combination in the tc.	